Intermediate-Size Expanded Access in Jordan

About Intermediate-Size Expanded Access

US FDA framework for groups of patients.

How Intermediate-Size Expanded Access works in Jordan

Jordan's JFDA operates a compassionate-use framework for unregistered drugs; requires physician and JFDA approval.

Patients in Jordan seeking access under Intermediate-Size Expanded Access typically follow this flow: a licensed physician in Jordan issues the prescription and clinical justification, the regulator reviews and authorises, and an authorised operator coordinates import.

Documents required in Jordan

• Physician prescription and clinical-justification letter.
• Patient identification and consent.
• Country-specific NPP/personal-import form.
• Hospital or clinic attestation where required.

Typical timeline

End-to-end 2-6 weeks in most tier 2 jurisdictions. Cellular and gene therapies may require additional ethics-committee review.

Start a request

Start a request under Intermediate-Size Expanded Access in Jordan